Testing effectiveness (Phase 2)Ended earlyNCT02996448
What this trial is testing
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
Who this might be right for
Autosomal-dominant Hyper-IgE Syndrome
National Institute of Allergy and Infectious Diseases (NIAID) 3